Antimicrobial Agents | Methods for Diagnostic & Therapeutic Studies | Liver Biology & Pathobiology | Liver Failure & Liver Disease | Viral Hepatitis
Prediction of response to peginterferon for HBeAg-positive chronic hepatitis B using quantitative serology: HBeAg versus HBsAg
Milan J Sonneveld*, Vincent Rijckborst, Bettina E Hansen, Harry LA Janssen
*Corresponding author: Milan J Sonneveld
Departments of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, Netherlands
F1000Posters 2012, 3: 471 (poster) [English]
47th Annual International Liver Congress 2012, 18 - 22 Apr 2012, 543
Recent studies have proposed to use serum levels of HBeAg and HBsAg to predict response to peginterferon (PEG-IFN) therapy for chronic hepatitis B (CHB). However, the predictive capabilities of these markers have not been compared in a large cohort of patients treated with peginterferon.
The aim of this study is to compare the positive and negative predictive values of two recently proposed prediction rules based on serum levels of HBeAg and HBsAg.
Serum HBsAg levels appear to be superior to serum HBeAg levels for prediction of response to PEG-IFN therapy.
No relevant competing interests disclosed.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the CC BY-NC Creative Commons 3.0 License